

| | |
|-------------------------|-------------------------------------|
| Reference: | FOI.16400.25 |
| Subject: | Intravitreal injections or implants |
| Date of Request: | 17 January 2025 |

Requested:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2024:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2024:

Number of Injections/Implants: September to December 2024:

| Treatment | Eye Conditions | | |
|--|---|-------------------------------|------------------------------|
| | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) |
| Aflibercept | | | |
| Bevacizumab | | | |
| Dexamethasone | | | |
| Faricimab | | | |
| Ranibizumab - Lucentis | | | |
| Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) | | | |

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of intravitreal injections/implants administered for the medications listed, during the period 1 September to 31 December 2024.

| Medication | Number |
|---------------|--------|
| Aflibercept | 1,026 |
| Bevacizumab | 0 |
| Brolucizumab | * |
| Dexamethasone | 122 |
| Faricimab | 1,255 |

| | |
|--|-------|
| Fluocinolone acetonide | 9 |
| Ranibizumab - Lucentis | 99 |
| Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) | 1,403 |

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. The UHB provides, within the table below as requested, the number of intravitreal injections/implants administered for the medications listed, by eye condition, during the period 1 September to 31 December 2024.

| Treatment | Eye Conditions | | |
|--|---|-------------------------------|------------------------------|
| | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) |
| Aflibercept | 519 | 160 | 204 |
| Bevacizumab | 0 | 0 | 0 |
| Dexamethasone | 7 | 47 | 59 |
| Faricimab | 998 | 130 | 89 |
| Ranibizumab - Lucentis | 64 | 13 | 18 |
| Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) | 920 | 159 | 201 |